"Hydroxybutyrates" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Salts and esters of hydroxybutyric acid.
| Descriptor ID |
D006885
|
| MeSH Number(s) |
D02.241.081.114.937 D02.241.511.429 D10.251.400.143.781
|
| Concept/Terms |
Hydroxybutyric Acids- Hydroxybutyric Acids
- Hydroxybutyric Acid Derivatives
- Acid Derivatives, Hydroxybutyric
|
Below are MeSH descriptors whose meaning is more general than "Hydroxybutyrates".
Below are MeSH descriptors whose meaning is more specific than "Hydroxybutyrates".
This graph shows the total number of publications written about "Hydroxybutyrates" by people in this website by year, and whether "Hydroxybutyrates" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 0 | 2 | 2 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 4 | 4 |
| 2021 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Hydroxybutyrates" by people in Profiles.
-
Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors "leflunomide" and "teriflunomide" in Covid-19: A narrative review. Eur J Pharmacol. 2021 Sep 05; 906:174233.
-
COVID-19 in Argentine teriflunomide-treated multiple sclerosis patients: First national case series. Mult Scler Relat Disord. 2021 Aug; 53:103049.
-
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. CNS Drugs. 2021 03; 35(3):317-330.
-
The serum metabolome of COVID-19 patients is distinctive and predictive. Metabolism. 2021 05; 118:154739.
-
Transient monocular visual impairment as an initial symptom of COVID-19 infection in an individual with multiple sclerosis receiving teriflunomide. Neurol Sci. 2021 May; 42(5):1661-1664.
-
COVID-19 in teriflunomide-treated patients with multiple sclerosis: A case report and literature review. Mult Scler Relat Disord. 2021 Feb; 48:102734.
-
Impact of coronavirus disease (COVID-19) pandemic on multiple sclerosis care. Clin Neurol Neurosurg. 2020 10; 197:106203.
-
Mild COVID-19 infection in a group of teriflunomide-treated patients with multiple sclerosis. J Neurol. 2021 Jun; 268(6):2029-2030.
-
Dihydroorotate dehydrogenase inhibitors in SARS-CoV-2 infection. Eur J Clin Invest. 2020 Oct; 50(10):e13366.
-
Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2. Protein Cell. 2020 10; 11(10):723-739.